GlaxoSmithKline places a risky bet on Arrowhead's RNA drug in the failure-strewn NASH field
As activist investors champ at the bit for change at drug giant GlaxoSmithKline, the pharma giant has turned over many rocks to find an R&D success to present to its detractors. In NASH, a field strewn with failures, GSK hopes a new license deal can churn out a much-needed winner.
GSK will pay $120 million in upfront cash and $910 million in downstream milestones to develop and sell ARO-HSD, Arrowhead Pharmaceuticals’ RNA interference drug targeting fatty liver disease nonalcoholic steatohepatitis (NASH), the companies said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.